We invite cardiothoracic surgeons to join us at this year's SECCE in Madrid. Here, we’ll dive into the latest advancements in #Afib ablation techniques and #LAAE using our state-of-the-art heart simulation model. Learn more: okt.to/v65rkH #MedEd #CardioTwitter #SECCE

AtriClip® is the most widely sold LAAM device globally. Our commitment to excellence and innovation continues to make a difference in patients' lives.

Discover why surgeons worldwide trust AtriClip: okt.to/KzBj7a
#AtriClip #LAAM #CardioTwitter

Congratulations to Dr. Steven Hunter and his team at Sheffield Hospitals for the 1st first UK patient enrolled in the LeAAPS™ trial!​

LeAAPS is the largest randomized clinical trial in cardiac surgery history and will assess whether LAAE using AtriClip™ devices can reduce stroke

Join us at #HRS2024 to discover how you can enhance outcomes for LSPAF patients. With remarkable results like over 98% Afib burden reduction at 12 months, #HybridAFTherapy might be the breakthrough your patients need.

See more of the data: okt.to/GlIgOS
Heart Rhythm Society

Our #HybridAFTherapy Programs in Amsterdam, Netherlands highlights the rationale, efficiency, & efficacy of a dual approach between cardiac surgeons and EPs when treating LSPAF patients. 
Register for our upcoming program and find more details at AFConnect.eu​. #Epeeps

Reduced antiarrhythmic drug use, superior freedom from Atrial Arrhythmia recurrence* and fewer repeat ablations are just a few of the positive outcomes we’re seeing two years out with the randomized-controlled CEASE-AF Trial using Hybrid ablation and LAAE compared to endocardial

Cryo Nerve Block provides non-opioid pain relief, numbing the surgical site for up to 3 months.

cryoNB is a crucial addition to pain-management care as options can become limited post-op.

Learn more about #cryoNB : okt.to/5NXuSR
#PatientsFirst #CardioTwitter

At #AATS2024 , we engaged with physicians from around the globe, delving into the forefront of Afib treatment and post-op pain management. Of particular significance was Dr. McCarthy's presentation on the impactful effects of LAAE in non-AF cardiac patients. Witnessing such

AtriCure is dedicated to addressing the underserved market of those affected by Afib and post-op pain. With Q1 wrapped, we’re proud to report a strong first quarter.
 
Read the full earnings report at: okt.to/dB91iA
#FinancialResults #Earnings

At #AATS2024 , we had the opportunity to speak with Dr. McCarthy about the latest findings regarding surgical LAA exclusion in non-Afib cardiac patients and its potential implications. Tune in to hear his insights.
 
Read the abstract: okt.to/tNwZ6j 
#CardioTwitter

Two years out and the CEASE -AF Trial demonstrated superior freedom from atrial arrhythmias* in patients with advanced disease who underwent staged hybrid ablation + left atrial appendage exclusion compared to endocardial ablation alone. ​
​
See the data: bit.ly/3xth6Qi

Dr. Dasilva brought Cryo Nerve Block to AdventHealth Cancer Institute in 2021. Now accompanied by Drs. Gaughan & Chmielewski, they've treated 300+ patients in 3 years.

Discover why thoracic surgeons are embracing cryoNB for post-op pain relief: bit.ly/cryo-nerve-blo…
#cryoNB

New data presented at AATS found that in patients without diagnosed pre-op Atrial Fibrillation (AF), the primary outcome, ischemic stroke had lower event rates and odds ratios (OR) for LAAE at 30 days. See the data: okt.to/Ama2lf
#AATS2024 #CardioTwitter

Are you at #AATS2024 ? Stop by our booth #905 and the surgical suite at #105 for an unparalleled hands-on learning experience using simulation models, featuring Hybrid AF™ Therapy for LSPAF patients, LAA exclusion and Cryo Nerve Block for post-op pain management.
#CardioTwitter

Breaking news! New data presented during #AATS2024 by Dr. Patrick McCarthy concluded surgical LAA exclusion during open cardiac surgery in patients without Afib was associated with 4 years of ischemic stroke and mortality benefit. See the full abstract: okt.to/l6piA5

Stop by our booth tomorrow at #AATS2024 to meet with our team of experts to discuss the importance and value of LAAE, now a Class 1A recommendation, and how Hybrid AF™ Therapy can benefit your LSPAF patients. Plus, get hands-on with our simulation model. 
#CardioTwitter #Epeeps

Congratulations to Barts Heart Centre, St George's University Hospital, and Bristol Heart Institute for pioneering the first UK cases with EPi-Sense ST™! EPi-Sense ST offers a new approach to ablation procedures, allowing surgeons to fine-tune their technique using deflection

EPi-Sense ST™ is now MDR approved and available across Europe for the treatment of Advanced Afib patients! The first European cases recently took place at Rigshospitalet IM MONTSOURIS Asklepios Kliniken Deutsches Herzzentrum der Charité and C. C. Monzino.

Learn more about EPi-Sense ST:

Interested in learning the impact of surgical LAA exclusion in non-Afib patients from a real-world data set? Join Dr. Patrick McCarthy at #AATS24 on Sunday, April 28, for the Presidential Recognition abstract.
#Cardiotwitter #LAAE #MedEd

Discover Cryo Nerve Block at #AATS2024 ! Join us Saturday, 7 p.m., to explore its role in post-op pain management for thoracic procedures. Learn about its mechanism, patient referrals, and expectations, plus engage in a round table on professional experiences. Secure your spot: